Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215208 | 1.00 | KDM1A (0.47) | KDM1ASRD5A1KDM1BSLC6A2HTR2A | |
| SCHEMBL584522 | 1.00 | KDM1A (0.47) | KDM1ASRD5A1KDM1BSLC6A2HTR2A | |
| Hydrochloric Acid SCHEMBL1868816 | 0.98 | KDM1A (0.50) | KDM1ASRD5A1KDM1BSLC6A2HTR2A | |
| Hydrochloric Acid SCHEMBL16536660 | 0.98 | KDM1A (0.50) | KDM1ASRD5A1KDM1BSLC6A2HTR2A | |
| SCHEMBL14575715 | 0.89 | KDM1A (0.45) | KDM1ASRD5A1KDM1BSLC6A2HTR2A | |
| SCHEMBL27080967 | 0.89 | KDM1A (0.45) | KDM1ASRD5A1KDM1BSLC6A2HTR2A | |
| SCHEMBL27080511 | 0.89 | KDM1A (0.45) | KDM1ASRD5A1KDM1BSLC6A2HTR2A | |
| SCHEMBL32667464 | 0.87 | KDM1A (0.44) | KDM1ASRD5A1KDM1BSLC6A2HTR2A | |
| SCHEMBL16793923 | 0.87 | KDM1A (0.44) | KDM1ASRD5A1KDM1BSLC6A2HTR2A | |
| Hydrochloric Acid SCHEMBL16793858 | 0.85 | KDM1A (0.46) | KDM1ASRD5A1KDM1BSLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065436-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-08-20 | — | — | US | claimed |
| US-20230119665-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | claimed |
| CN-105175272-A | Method for preparing R-5-bromo-1-aminoindane | WU LING | 2015-12-23 | — | — | CN | claimed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | TERREMOTO BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260028348-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4685149-A1 | NOVEL COMPOUND AS ENDOTHELIAL TO MESENCHYMAL TRANSITION (ENDMT) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Korea Institute of Radiological & Medical Sciences (KR) | 2026-01-28 | — | — | EP | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025081045-A9 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4380932-B1 | PROCESS FOR PREPARING AFICAMTEN | CYTOKINETICS INC (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250353817-A1 | INTERLUKIN-17A INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20140080756-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES | PFIZER INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8609680-B2 | 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives | PFIZER INC. (US) | 2013-12-17 | — | — | US | disclosed |
| EP-2547679-A1 | 2,3 DIHYDRO-1H-INDEN-1-YL- 2,7-DIAZASPIRO [3.6]NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR | Pfizer Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| WO-2011114271-A1 | 2,3 DIHYDRO-1H-INDEN-1-YL- 2,7-DIAZASPIRO [3.6] NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR | PFIZER INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011114271-A1 | 2,3 DIHYDRO-1H-INDEN-1-YL- 2,7-DIAZASPIRO [3.6] NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR | PFIZER INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119665-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | KDM1A 2201/4885SRD5A1 862/4885KDM1B 1990/4885 |
| US-20250353817-A1 | INTERLUKIN-17A INHIBITORS AND USES THEREOF | IL17A, IL15, IL23R | KDM1A 2839/4885SRD5A1 1618/4885KDM1B 3373/4885 |
| US-12065436-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | KDM1A 2201/4885SRD5A1 862/4885KDM1B 1990/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | KDM1A 405/4885SRD5A1 575/4885KDM1B 345/4885 |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | AKT1, AKT2, AKT3 | KDM1A 2806/4885SRD5A1 1392/4885KDM1B 2123/4885 |
| US-20140080756-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES | GIPR, GLP1R, GHSR | KDM1A 1315/4885SRD5A1 963/4885KDM1B 1766/4885 |
| US-20260028348-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, TNFRSF9 | KDM1A 3418/4885SRD5A1 361/4885KDM1B 3886/4885 |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | GIPR, GLP1R, GHSR | KDM1A 1217/4885SRD5A1 947/4885KDM1B 1644/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | KDM1A 1493/4885SRD5A1 2105/4885KDM1B 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.